Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 7/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | LAP3 | P28838 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5996997 | 1.00 | BTN3A1 (0.40) | BTN3A1ELANEPKMHTTSRC | |
| SCHEMBL10004082 | 0.90 | CA1 (0.38) | PKMHTTHPGD | |
| SCHEMBL4273088 | 0.88 | ELANE (0.38) | BTN3A1ELANESRCPRTN3L3MBTL1 | |
| SCHEMBL1811991 | 0.88 | HPGD (0.39) | HTTL3MBTL1LMNAPOLBNPSR1 | |
| SCHEMBL1807789 | 0.86 | CYP1A2 (0.37) | LMNAPOLBMAPK1HPGD | |
| SCHEMBL2012767 | 0.86 | ELANE (0.40) | BTN3A1ELANEPKMHTTSRC | |
| SCHEMBL2008561 | 0.86 | LMNA (0.41) | LMNATDP1POLBNPSR1MAPK1 | |
| SCHEMBL2008560 | 0.86 | LMNA (0.41) | LMNATDP1POLBNPSR1MAPK1 | |
| SCHEMBL2012770 | 0.86 | ELANE (0.40) | BTN3A1ELANEPKMHTTSRC | |
| SCHEMBL7023448 | 0.86 | APP (0.32) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12121529-B2 | Nucleoside phosphoramidate prodrugs | GILEAD SCIENCES, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| EP-2203462-B2 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | GILEAD PHARMASSET LLC (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20240139227-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | GILEAD PHARMASSET LLC | 2024-05-02 | — | — | US | disclosed |
| EP-4282482-A2 | Nucleoside phosphoramidate prodrugs | Gilead Sciences, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-2801580-B1 | Nucleoside phosphoramidate prodrugs | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230192750-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2023-06-22 | — | — | US | disclosed |
| US-11642361-B2 | Nucleoside phosphoramidate prodrugs | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11560400-B2 | Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds | NuCana plc (GB) | 2023-01-24 | — | — | US | disclosed |
| EP-3904365-B1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2022-09-07 | — | — | EP | disclosed |
| EP-2937350-B9 | 1' -substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES INC (US) | 2022-08-17 | — | — | EP | disclosed |
| EP-1090018-A1 | ARYL PHOSPHATE DERIVATIVES OF d4T HAVING ANTI-HIV ACTIVITY | Parker Hughes Institute (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2001007088-A2 | METHODS FOR TREATING THERAPY-RESISTANT TUMORS | NEWBIOTICS, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001007454-A1 | ENZYME CATALYZED THERAPEUTIC ACTIVATION | NEWBIOTICS, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-1045897-A4 | ENZYME CATALYZED THERAPEUTIC AGENTS | NEWBIOTICS INC (US) | 2000-10-25 | — | — | EP | disclosed |
| EP-1045897-A1 | ENZYME CATALYZED THERAPEUTIC AGENTS | Newbiotics Inc. (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-2000047591-A1 | PHOSPHORAMIDATE, AND MONO-, DI-, AND TRI-PHOSPHATE ESTERS OF (1R, CIS)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL AGENTS | GLAXO GROUP LIMITED (GB) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000018775-A1 | ANTIVIRAL PURINE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
| US-6030957-A | INHIBITING HIV(HUMAN IMMUNODEFICIENCY VIRUS) REVERSE TRANSCIPTASE IN CELLS INFECTED WITH HIV BY ADMINISTERING TO INFECTED CELLS ARYLPHOSPHATE DERIVATIVE OF 2',3'-DIDEHYDRO-2',3'-DIDEOXYTHYMIDINE | WAYNE HUGHES INSTITUTE (US) | 2000-02-29 | — | — | US | disclosed |
| WO-2000000501-A1 | ARYL PHOSPHATE DERIVATIVES OF d4T HAVING ANTI-HIV ACTIVITY | PARKER HUGHES INSTITUTE (US) | 2000-01-06 | — | — | WO | disclosed |
| WO-1999037753-A1 | ENZYME CATALYZED THERAPEUTIC AGENTS | NEWBIOTICS, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139227-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PNP, NUDT1, TYMP | BTN3A1 4740/4885ELANE 841/4885PKM 1403/4885 |
| US-20230192750-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | NUDT1, TYMP, NTPCR | BTN3A1 4850/4885ELANE 3120/4885PKM 2717/4885 |
| US-11642361-B2 | Nucleoside phosphoramidate prodrugs | PNP, NUDT1, TYMP | BTN3A1 4740/4885ELANE 841/4885PKM 1403/4885 |
| US-12121529-B2 | Nucleoside phosphoramidate prodrugs | PNP, NUDT1, TYMP | BTN3A1 4740/4885ELANE 841/4885PKM 1403/4885 |
| US-11560400-B2 | Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds | NUDT1, NTPCR, TYMP | BTN3A1 4837/4885ELANE 2566/4885PKM 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.